These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 22253423)
21. Effects of telmisartan and olmesartan on insulin sensitivity and renal function in spontaneously hypertensive rats fed a high fat diet. Yanagihara H; Ushijima K; Arakawa Y; Aizawa K; Fujimura A J Pharmacol Sci; 2016 Jul; 131(3):190-7. PubMed ID: 27430988 [TBL] [Abstract][Full Text] [Related]
22. Effects of telmisartan and valsartan on insulin sensitivity in obese diabetic mice. Ushijima K; Takuma M; Ando H; Ishikawa-Kobayashi E; Nozawa M; Maekawa T; Shiga T; Fujimura A Eur J Pharmacol; 2013 Jan; 698(1-3):505-10. PubMed ID: 23195328 [TBL] [Abstract][Full Text] [Related]
23. Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet. Souza-Mello V; Gregório BM; Cardoso-de-Lemos FS; de Carvalho L; Aguila MB; Mandarim-de-Lacerda CA Clin Sci (Lond); 2010 Jun; 119(6):239-50. PubMed ID: 20415664 [TBL] [Abstract][Full Text] [Related]
24. An adipose tissue-independent insulin-sensitizing action of telmisartan: a study in lipodystrophic mice. Rong X; Li Y; Ebihara K; Zhao M; Aini W; Kusakabe T; Hirata M; Miyamoto L; Murray M; Nakao K J Pharmacol Exp Ther; 2009 Dec; 331(3):1096-103. PubMed ID: 19770292 [TBL] [Abstract][Full Text] [Related]
25. Telmisartan increases fatty acid oxidation in skeletal muscle through a peroxisome proliferator-activated receptor-gamma dependent pathway. Sugimoto K; Kazdová L; Qi NR; Hyakukoku M; Kren V; Simáková M; Zídek V; Kurtz TW; Pravenec M J Hypertens; 2008 Jun; 26(6):1209-15. PubMed ID: 18475159 [TBL] [Abstract][Full Text] [Related]
26. Lack of weight gain after angiotensin AT1 receptor blockade in diet-induced obesity is partly mediated by an angiotensin-(1-7)/Mas-dependent pathway. Schuchard J; Winkler M; Stölting I; Schuster F; Vogt FM; Barkhausen J; Thorns C; Santos RA; Bader M; Raasch W Br J Pharmacol; 2015 Aug; 172(15):3764-78. PubMed ID: 25906670 [TBL] [Abstract][Full Text] [Related]
27. TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation. Iwai M; Chen R; Imura Y; Horiuchi M Am J Hypertens; 2007 May; 20(5):579-86. PubMed ID: 17485025 [TBL] [Abstract][Full Text] [Related]
28. Chronic blockade of angiotensin AT₁ receptors improves cardinal symptoms of metabolic syndrome in diet-induced obesity in rats. Müller-Fielitz H; Hübel N; Mildner M; Vogt FM; Barkhausen J; Raasch W Br J Pharmacol; 2014 Feb; 171(3):746-60. PubMed ID: 24490862 [TBL] [Abstract][Full Text] [Related]
29. Effect of telmisartan, angiotensin II receptor antagonist, on metabolic profile in fructose-induced hypertensive, hyperinsulinemic, hyperlipidemic rats. Kamari Y; Harari A; Shaish A; Peleg E; Sharabi Y; Harats D; Grossman E Hypertens Res; 2008 Jan; 31(1):135-40. PubMed ID: 18360028 [TBL] [Abstract][Full Text] [Related]
30. Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists. Erbe DV; Gartrell K; Zhang YL; Suri V; Kirincich SJ; Will S; Perreault M; Wang S; Tobin JF Vascul Pharmacol; 2006 Sep; 45(3):154-62. PubMed ID: 16765099 [TBL] [Abstract][Full Text] [Related]
37. Effects of angiotensin II receptor antagonists on insulin resistance syndrome and leptin in sucrose-fed spontaneously hypertensive rats. Umeda M; Kanda T; Murakami M Hypertens Res; 2003 Jun; 26(6):485-92. PubMed ID: 12862206 [TBL] [Abstract][Full Text] [Related]
38. Neuroendocrine characterization and anorexigenic effects of telmisartan in diet- and glitazone-induced weight gain. Aubert G; Burnier M; Dulloo A; Perregaux C; Mazzolai L; Pralong F; Zanchi A Metabolism; 2010 Jan; 59(1):25-32. PubMed ID: 19793594 [TBL] [Abstract][Full Text] [Related]
39. Telmisartan improves survival and ventricular function in SHR rats with extensive cardiovascular damage induced by dietary salt excess. Susic D; Frohlich ED J Am Soc Hypertens; 2014 May; 8(5):297-302. PubMed ID: 24726099 [TBL] [Abstract][Full Text] [Related]
40. Partial agonist, telmisartan, maintains PPARγ serine 112 phosphorylation, and does not affect osteoblast differentiation and bone mass. Kolli V; Stechschulte LA; Dowling AR; Rahman S; Czernik PJ; Lecka-Czernik B PLoS One; 2014; 9(5):e96323. PubMed ID: 24810249 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]